Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Myeloid, Acute 1Leukemia 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Bronchiolitis Obliterans Syndrome 1Brain Neoplasms 1

Interventions

Cyclophosphamide 14fludarabine phosphate 9Bortezomib 9Brentuximab Vedotin 7Filgrastim 6Vorinostat 5Doxorubicin 5tanespimycin 4Whole-Body Irradiation 4Vincristine 4Peripheral Blood Stem Cell Transplantation 4Paclitaxel 4Gemcitabine 4Cyclosporine 4Cord Blood Stem Cell Transplantation 4Carboplatin 4Biopsy 4sargramostim 3romidepsin 3fludarabine 3Topotecan 3Rifampin 3Prednisone 3Mycophenolic Acid 3Magnetic Resonance Spectroscopy 3Leucovorin 3Lenalidomide 3Irinotecan 3Fluorouracil 3Everolimus 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Large-Cell, Anaplastic × Interleukin-15 × Clear all
NCT03905135 2022-09-13

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
8 enrolled 18 charts
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡